Centre Hospitalier de la Côte Basque-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2013

  1. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 14, Núm. 11, pp. 1055-1066